{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.2","upperLimit":"86.3","value":"82.3"},{"groupId":"OG001","lowerLimit":"66.3","upperLimit":"77.0","value":"72.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"432"},{"groupId":"OG001","value":"429"}],"units":"Participants"}],"description":"The OS rate was determined for all participants at Month 18 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 18 is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.","id":"OG000","title":"Pembrolizumab + Axitinib"},{"description":"Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.","id":"OG001","title":"Sunitinib"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"Month 18","title":"Overall Survival (OS) Rate at Month 18 in All Participants","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}